



ORIGINAL ARTICLE

Comparison of pneumococcal vaccination response in children with sickle cell disease: HbSS and HbSC

X. Le Ng, M. Alikhan, J.M. Stark, R.A. Mosquera, S. Shahrukh Hashmi, T. Gonzales, D.L. Brown, T.T. Nguyen, A. Yadav*

Department of Pediatrics, McGovern Medical School, University of Texas Health Science Center, Houston, TX, USA

Received 27 November 2018; accepted 5 April 2019
Available online 1 June 2019

KEYWORDS
Sickle cell disease;
HbSS;
HbSC;
Immunity;
Pneumococcus;
Vaccine

Abstract

Introduction: Sickle cell disease (SCD) children are at increased risk of invasive pneumococcal disease and rely on penicillin prophylaxis and vaccination for infection prevention. Post-vaccination antibody levels in SCD may wane overtime. HbSC are believed to have better immunological response than HbSS.

Objective: To compare antibody response to 23-valent pneumococcal polysaccharide vaccine (PPSV-23) between HbSS and HbSC.

Methods: Patients with HbSS ($n=33$) and HbSC ($n=11$), aged 7–18 years, were prospectively recruited. Luminex pneumococcal antibody levels were measured for 23-serotypes, after two PPSV-23 doses.

Results: Absolute median titer for 20 of the 23 serotypes was higher in HbSC than HbSS and significantly higher for serotypes 22 (3.9 vs. 1.6 mcg/ml; $p=0.039$) and 43 (2.9 vs. 0.8 mcg/ml; $p=0.007$). HbSC mounted a better immune anti-pneumococcal response compared to HbSS (≥ 1.3 mcg/ml) for 18 of 23 serotypes, albeit not significant for any of the serotypes. More HbSC (64%) than HbSS (42%) were good vaccine responders ($p=0.303$). Two of 21 (10%) good vaccine responders and nine of 23 (39%) poor vaccine responders SCD participants subsequently developed acute chest syndrome or pneumonia ($p=0.036$). None of the HbSC patients developed ACS after receiving PPSV-23. HbSS poor vaccine responders were at increased future recurrence risk for ACS ($p=0.003$), pneumonia ($p=0.036$) or both ($p=0.011$), compared to good vaccine responders.

Conclusion: HbSC possess better pneumococcal vaccine response than HbSS. Poor vaccine response is concerning for future acute pulmonary events. Current vaccination strategy for SCD sub-types are lacking, therefore further study to evaluate utility of vaccine boosters is necessary.

© 2019 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Abbreviations: IPD, invasive pneumococcal disease; NLHBI, national Heart Lung and Blood Institute; PCV, pneumococcal conjugate vaccine; PPSV-23, 23-valent pneumococcal polysaccharide vaccine; SCD, sickle cell disease; ACS, acute chest syndrome.

* Corresponding author.

E-mail address: aravind.yadav@uth.tmc.edu (A. Yadav).

<https://doi.org/10.1016/j.aller.2019.04.003>

0301-0546/© 2019 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Introduction

Sickle cell disease (SCD) is the most common inherited hematologic disorder in the United States. Previous studies have established that individuals with SCD are at higher risk of infections, particularly by encapsulated bacteria such as *Streptococcus pneumoniae*.¹ The single most common cause of death in children with SCD is *Streptococcus pneumoniae* sepsis.^{1,2} The unusual susceptibility results from two immunological problems; (1) splenic malfunction, and (2) failure to make specific IgG antibodies to polysaccharide antigens. As a result of this increased risk, children with SCD are heavily reliant on both early penicillin prophylaxis and anti-pneumococcal vaccination for prevention of invasive pneumococcal disease (IPD). The current ACIP guidelines released by the National Heart Lung and Blood Institute (NHLBI) recommend all children complete the primary PCV-13 series, and SCD children also receive the 23-valent polysaccharide anti-pneumococcal vaccine (PPSV-23) but recommendations regarding additional doses was not specified.³

Children with SCD typically do not respond to the pneumococcal vaccine as well as otherwise healthy children. Although the overall immune response is poor, a rise in IgG antibodies against the most immunogenic polysaccharides and a lower response to less immunogenic polysaccharides is often noted. IgG antibody concentrations in five-year-old children with SCD, who were previously immunized with one or two doses of the polysaccharide vaccine were found to have levels similar to those of unimmunized healthy children. Apparently there was no evidence that the polysaccharide vaccine provided a "booster" effect.⁴ Only 36% of SCD patients had sustained anti-pneumococcal protective antibody levels three years following vaccination.⁵ The less-immunogenic antigens are likely responsible for vaccine failures.

Some studies have demonstrated that it was safe to discontinue prophylactic penicillin at age five.⁶ Despite these results, some clinicians still continue prophylaxis beyond age five years, but this approach is less popular now that penicillin resistant organisms have emerged.⁷ A "just in time" approach is sometimes suggested as an alternative to prophylaxis for children with HbSC or HbS β^{thal+} , whereupon the incidence of *Streptococcus pneumoniae* sepsis is lower than in sickle cell anemia (HbSS). Studies show that up to 69% of pediatric hematologists stop penicillin prophylaxis and rely on immunizations to prevent IPD after the age five of years.⁸

Patients with HbSS and HbSC are believed to have differing immune responses to vaccination, but a direct comparison between the two groups has not previously been performed. We hypothesized that children with HbSC had a better immune response to pneumococcal vaccination than HbSS.

Materials and methods

Study design and participants

In this prospective study, all patients aged 18 and below having a confirmed diagnosis of SCD with hemoglobin subtypes HbSS and HbSC seen at our institute during a maintenance

visit at a steady state with no acute pain crisis, hospitalization, fever or blood transfusion in the previous four weeks, were included. The comprehensive sickle cell center is a major urban tertiary referral center and medical home for sickle cell patients in the region, providing multidisciplinary care to our patients, including hematology, primary care, pulmonary, psychiatry, social worker and nurse coordinator. Subjects had to have undergone vaccination response testing at least four weeks after receiving two doses of PPSV-23 (Pneumovax[®]) vaccines. Per guidelines at our institute, all SCD patients receive one dose of PPSV-23 of 0.5 ml between the ages of two to five years, followed by a second dose of 0.5 ml five years thereafter; as a preventive measure given the high risk of invasive pneumococcal disease among the SCD patients. We did not find any children younger than age seven years who had received two doses of PPSV. The study was approved by the institutional review board (IRB number: HSC-MS-17-0937).

Subjects would also have received PCV (pneumococcal conjugate vaccine) based on vaccination schedule. Subjects with unknown history of immunization, fewer than two doses of PPSV, unknown levels of pneumococcal antibody titers, history of chronic blood transfusion or recent blood transfusion within the past four weeks and history of known immunodeficiency, including splenectomy were excluded from the study. Demographic data such as age, gender, and SCD subtype, immunization history and anti-pneumococcal immunoglobulin titers done in commercial laboratory, documentation of acute chest syndrome (ACS) or pneumonia in the medical record were obtained. The tested serotypes titers (American nomenclature) correspond to those covered by PPSV-23 (Pneumovax[®]), including 1, 2, 3, 4, 5, 8, 9, 12, 14, 17, 19, 20, 22, 23, 26, 34, 43, 51, 54, 56, 57, 68 and 70. Of the 118 children seen at our institute 51 were ineligible due to receiving only one dose of PPSV and five were excluded due to history of splenectomy ($n=2$), chronic blood transfusions ($n=2$) and lost to follow up ($n=1$). Forty-four eligible subjects (72%) eventually completed the study. (Fig. 1)

Vaccine response assessment

The vaccination response testing was performed as part of the routine comprehensive assessment at our center. Immunoglobulin levels were measured using Luminex multiple analyte profiling system, using quantitative multiplex bead assay done by commercial labs.^{9,10} Luminex multiple analyte profiling involves a flow cytometric system that allows for single sample testing against multiple analytes. This technique utilizes competitive inhibition binding at various dilutions with 1-h incubation periods in order to assess serum immunogenicity against a wide array of pneumococcal serotypes. An individual patient's immune response is defined both per serotype as well as the overall vaccination response to all serotypes tested.

Interpretation of pneumococcal vaccine response

Patients are considered to be "good vaccine responders" if their serum IgG levels were ≥ 1.3 mcg/ml to at least 70% of the 23 pneumococcal serotypes tested (i.e. more than 16 serotypes with levels of greater than or equal to 1.3 mcg/ml)

118 children with Sickle Cell subtypes SS and SC




Figure 1 Children with sickle cell subtypes SS and SC.

based on previous reports.^{11,12} Patients who responded to 15 or less of the designated serotypes were defined as "poor vaccine responders".

Statistical analysis

Analyses were conducted using Stata statistical software (v14, StataCorp LP, College Station, TX, USA). Categorical data are reported as frequencies (with percentages) and comparisons across categorical variables were performed using chi-square or Fisher exact test. Continuous data was described using means (with standard deviations, SD) and medians (with interquartile ranges, IQR) for data that was normally and not normally distributed, respectively. The distribution of these variables was compared between the SS and SC patient groups using a *t*-test (if normally distributed) or a Mann–Whitney test (if not normally distributed).

Results

Pneumococcal vaccination titers were collected on all patients seen at our pediatric sickle cell center who had been vaccinated with PPSV-23. Of the 118 children, 61

subjects were eligible although 44 (72%) eventually completed the study (Fig. 1). Of these, 21 were male (48%), 33 HbSS disease (75%), 11 HbSC (25%) and 28 (HbSS-27/33) on hydroxyurea (Table 1). The mean age of all subjects was 12.7 years, with a range of 7–18 years.

Prior to receiving the 2nd dose PPSV-23, 27 patients (22 HbSS and five HbSC) reported history of pneumonia or acute chest syndrome and one HbSS had *Streptococcus pneumoniae* sepsis. There was no significant difference in occurrence of ACS, pneumonia or sepsis between both hemoglobin sub-types (Table 1). After receiving two doses of PPSV-23, 11 patients (ten HbSS and one HbSC) were subsequently treated for pneumonia or acute chest syndrome. There was no significant difference in ACS or pneumonia between the hemoglobin sub-types. Of note, SCD patients with no prior ACS did not develop any ACS episodes even after the 2nd vaccine dose. These patients were not on penicillin prophylaxis during the episodes of pneumonia or acute chest syndrome.

The absolute median value of the titers among patients with HbSC was higher compared to HbSS patients to all 23-serovalents, except serotypes 9, 34 and 54. However, due to the considerable variability in the titer values for each patient, a statistically significant difference in these

Table 1 Comparison of demographic and medical history between HbSS and HbSC patients.

	SS (n = 33) ^a	SC (n = 11)	p-Values
<i>Age (years), median (IQR)</i>	11 (10–11)	16 (13–16)	0.007
<i>Age group, n (%)</i>			
7–10 years	14 (42)	1 (9)	0.067
11–18 years	19 (58)	10 (91)	
<i>Female gender, n (%)</i>	17 (52)	6 (55)	1.000
<i>Hydroxyurea, n (%)</i>	27 (84)	1 (9)	<0.001
<i>PCV immunization, n (%)</i>	33 (100)	11 (100)	1.000
<i>Percentage of reactive serotypes per patients, median (IQR)</i>	65 (57–87)	83 (65–91)	0.174
<i>Number of patients with ≥70% reactive serotypes, n (%)</i>	14 (42)	7 (64)	0.303
<i>History of infection before 2nd PPSV vaccine, n (%)</i>			
Acute Chest Syndrome	21 (64)	4 (36)	0.164
Pneumonia	10 (30)	3 (27)	1.000
Pneumonia or Acute Chest Syndrome	22 (67)	5 (45)	0.289
Sepsis	1 (3)	0 (0)	1.000
<i>History of infection after 2nd PPSV vaccine, n (%)</i>			
Pneumonia	5 (15)	1 (9)	1.000
Acute Chest Syndrome	8 (24)	0 (0)	0.170

^a Two SS patients had titer values for only 14 serotypes.

values (Table 2) was observed only for serotypes 22 (3.9 vs. 1.6 mcg/ml; $p=0.039$) and 43 (2.9 vs. 0.8 mcg/ml; $p=0.007$).

Subjects with HbSC mounted a better immune response to the pneumococcal vaccination compared to HbSS (serum IgG levels ≥ 1.3 mcg/ml). HbSC patients had 21 serotypes that were ≥ 1.3 mcg/ml, compared to 20 serotypes for HbSS. Percentage of HbSC mounting an adequate response, was equal to or higher than HbSS for 18 of the 23 serotypes, but there was no statistical difference between the groups (Table 2).

Patients with HbSC showed higher reactivity (serum IgG levels ≥ 1.3 mcg/ml to at least 70% of the 23 serotypes) than HbSS patients (Table 1). More HbSC patients 64% ($n=7$) were “good vaccine responders”, compared to 42% ($n=14$) HbSS patients ($p=0.303$).

In SCD patients post-vaccination, two of the 21 (10%) “good vaccine responders”, and nine of 23 (39%) “poor vaccine responders” subsequently went on to develop ACS or pneumonia ($p=0.036$). “Poor vaccine responders” ($n=8$, 100%) were significantly more likely than “good vaccine responders” to develop ACS ($p=0.004$) and more “poor vaccine responders” ($n=4$; 42%) than “good vaccine responders” ($n=2$; 10%) developed pneumonia ($p=0.423$). The occurrence of ACS, pneumonia, or both were not significantly different (Table 1) between both hemoglobin sub-types. Of note, all ACS after 2nd PPSV-23 ($n=8$) were HbSS, all of whom were “poor vaccine responders”. When vaccine response was assessed by hemoglobin sub-type to infection risk, HbSS “poor vaccine responders” ($n=19$) with a prior history of ACS ($n=14$), pneumonia ($n=4$), or both ($n=10$) were at significantly increased risk to subsequently develop ACS ($n=8$; $p=0.003$), pneumonia ($n=4$; $p=0.036$) or both ($n=9$; $p=0.011$), respectively when compared to “good vaccine responders”. All HbSC patients with previous ACS ($n=4$) were “good vaccine responders” and none

subsequently developed ACS. Of three HbSC with prior pneumonia, one “poor vaccine responder” developed pneumonia post-vaccination.

Discussion

Although rates of IPD in children with SCD have dropped dramatically since the introduction of pneumococcal conjugate vaccine, IPD rates in this population remain higher than in African-American children of the general population.¹³ Anti-pneumococcal immunity may not be optimally maintained in patients with SCD using current vaccination strategies, leaving them vulnerable to IPD. In this study, SCD patients tend to have a poor vaccine response, although HbSC mounted a better response than HbSS, particularly for serotypes 22 and 43, and a better overall vaccine response with lower incidences of acute pulmonary events. HbSC have a lower incidence of life-threatening infection because their spleen function is minimally impaired in early life. PPSV-23 elicits T cell independent IgM memory B cell in the presence of a mature spleen, but the response is attenuated in SCD related hypoplasia or asplenia.¹⁴ The loss of splenic function and ensuing reduction in opsonophagocytic activity is the most well accepted cause for the increased risk of infection with encapsulated bacteria, such as *Streptococcus pneumoniae*. Over time, all SCD genotypes develop an increased risk for invasive bacterial infection. In view of the reported perturbations of lymphocyte phenotypes and functions in HbSS, and accounts of impaired vaccine responsiveness in individuals with HbSS, it is possible that differences in vaccine reactivity exists between patients with SCD compared to that in individuals without SCD.¹⁵

Pneumococcal capsular serotypes can vary in their immunogenicity in sickle cell patients, demonstrating susceptibility to serotype 6, 26, 23⁴ as they are weak

Table 2 Median titer values and percentage of patients with titer values ≥ 1.3 mcg/ml for each serotype.

Serotype	Median titer values of each serotype (Interquartile range) ^a mcg/ml			Percentage of patients with titer value ≥ 1.3 mcg/ml for each serotype (Interquartile range)		
	HbSS	HbSC	p-Value	HbSS ^a	HbSC ^a	p-Value
1	1.8 (0.9–5.5)	2.2 (0.7–3.7)	0.957	22 (67)	8 (73)	1.000
2	1.3 (0.8–2.7)	2.8 (1.0–4.9)	0.086	16 (52)	7 (64)	0.726
3	4.0 (1.1–7.6)	5.7 (1.5–13.4)	0.349	24 (73)	10 (91)	0.408
4	2.1 (1.1–4.4)	3.9 (1.9–6.7)	0.238	22 (67)	9 (82)	0.461
5	5.1 (1.4–19.7)	14 (1.2–18.9)	0.461	24 (75)	8 (73)	1.000
8	2.2 (1.0–5.3)	3.1 (2.0–5.8)	0.322	22 (67)	10 (91)	0.240
9	1.7 (1.0–3.4)	1.6 (0.8–10.5)	0.957	20 (61)	7 (64)	1.000
12	0.3 (0.3–1.1)	0.6 (0.3–1.1)	0.376	6 (18)	2 (18)	1.000
14	5.1 (2.5–13.5)	14.1 (3.3–30.5)	0.228	29 (88)	10 (91)	1.000
17	1.3 (0.3–5.2)	1.7 (0.4–21.9)	0.404	17 (55)	7 (64)	0.731
19	11.3 (4–21.2)	18.3 (9.7–34.9)	0.255	32 (97)	10 (91)	0.442
20	2.3 (0.5–3.6)	4.6 (1.4–5.9)	0.156	19 (61)	9 (82)	0.283
22	1.6 (0.7–3)	3.9 (2.2–6.5)	0.039	19 (61)	9 (82)	0.283
23	3.1 (1.8–5.7)	9.9 (2.7–20.6)	0.061	26 (79)	10 (91)	0.656
26	9.4 (5.5–24.2)	15.6 (3.9–75.2)	0.551	32 (97)	10 (91)	0.442
34	1.4 (0.4–2.6)	1.2 (0.7–9.4)	0.329	16 (52)	5 (45)	1.000
43	0.8 (0.4–2.2)	2.9 (1.0–9.9)	0.007	12 (39)	7 (64)	0.180
51	3.8 (1.4–5.5)	5.5 (2.0–15.5)	0.175	25 (76)	10 (91)	0.411
54	2.0 (0.5–5.0)	1.3 (0.7–4.3)	0.699	18 (58)	6 (55)	1.000
56	2.6 (1.7–6.6)	3.7 (2.1–11)	0.158	25 (76)	11 (100)	0.170
57	9 (2.7–20.4)	14.9 (1.5–23.2)	0.504	28 (88)	10 (91)	1.000
68	2.3 (1.4–7.2)	3.1 (2.1–6.1)	0.448	25 (76)	10 (91)	0.411
70	1.1 (0.4–2.2)	2.9 (0.9–6.2)	0.132	14 (45)	6 (55)	0.730

^a N = 31–33 for SS patients and N = 11 for SC patients; significant findings p < 0.05 in bold.

immunogens, while serotype 3 induces a strong immune response and does not feature as a major cause for vaccine failure. It is possible that HbSS patients' compromised immune system may not mount an adequate response to certain serotypes compared to HbSC patients. We find differences in serotypes 22 and 43, both exclusively present in the PPSV-23 vaccine. In sickle cell populations, the incidence of pneumococcal disease caused by non-vaccine serotypes is increasing,¹³ although serotypes 22 and 43 did not feature as prominent causes of IPD.^{16,17} Serotype 43 has high carriage prevalence in children, but demonstrates low invasive potential.^{18,19} Serotype 22 on the other hand, was among replacement serotypes seen in children under five years of age after the introduction of the PCV-7.^{20–22} Selectively associated with the occurrence of meningitis, all serotype 22 isolates were susceptible to penicillin and should expectedly respond well to standard therapy.²¹

The overall poor vaccine response in both groups in this study, despite receiving a 2nd PPSV-23 dose is concerning, and in agreement with a previous report.⁵ In this study, a poor vaccine response was associated with increased acute pulmonary events, in particular for HbSS. HbSC mounted a better vaccine response than HbSS, and experienced less recurrence of complications. We postulate that poor vaccine response is a surrogate measure to poor immune status, and therefore SCD individuals are more prone to infections, an

important harbinger for acute chest syndrome. It is unclear if early intervention in poor vaccine responders could avert the risk of acute pulmonary events.

A limitation of this study was that we were unable to include healthy individuals because they receive a single dose of PPSV-23 vaccination. Pre-vaccination titers were not obtained for comparison. Ideally, post-vaccination samples obtained 4–8 weeks after immunization would be used to compare to pre-vaccination samples for individual serotypes. Due to concerns for interference with the efficacy of the PCV series, and obtaining titers only after 2nd dose PPSV-23, hence it would be difficult to establish an appropriate baseline timeframe to obtain pre-vaccine titers.^{11,12} For epidemiologic purposes, the number of pneumococcal serotypes that are protective after a vaccine is useful to define an adequate response.¹¹ The functionality of the anti-pneumococcal antibodies was not measured in this study as it is commercially unavailable.

In this unselected population, our data show overall poor vaccine response in SCD. Differences between HbSS and HbSC occur in immunogenic response to the pneumococcal vaccines. HbSC mount a better vaccine response than HbSS, leading to lower incidences of acute pulmonary events. Current vaccination strategies for SCD sub-types are lacking, therefore a larger study to evaluate the utility of additional vaccine boosters in children with SCD (HbSS and HbSC)

compared to the general population is necessary. Poor vaccine response is concerning, thus routine monitoring of vaccine response may be beneficial.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

All authors have no financial relationships relevant to this article to disclose.

Conflict of interest

All authors have no conflict of interest to disclose.

References

1. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. *Pediatrics*. 1989;84:500–8.
2. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative study of sickle cell disease. *Blood*. 1995;86:776–83.
3. National Heart Lung, and Blood Institute. Evidence-based management of sickle cell disease. Expert panel report, 2014.
4. Bjornson AB, Falletta JM, Verter JI, Buchanan GR, Miller ST, Pegelow CH, et al. Serotypespecific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. *J Pediatr*. 1996;129:828–35.
5. Santoro JD, Myers L, Kanter J. Assessing the immunogenic response of a single center's pneumococcal vaccination protocol in sickle cell disease. *J Pediatr Hematol Oncol*. 2016;38:e102–6.
6. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, Iyer RV, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. *J Pediatr*. 1995;127:685–90.
7. Chesney PJ, Wilimas JA, Presbury G, Abbasi S, Leggiadro RJ, Davis Y, et al. Penicillin- and cephalosporin-resistant strains of *Streptococcus pneumoniae* causing sepsis and meningitis in children with sickle cell disease. *J Pediatr*. 1995;127:526–32.
8. McCavit TL, Gilbert M, Buchanan GR. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts. *Pediatr Blood Cancer*. 2013;60:935–9.
9. Pickering JW, Martins TB, Greer RW, Schroder MC, Astill ME, Litwin CM, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. *Am J Clin Pathol*. 2002;117:589–96.
10. Zhang X, Simmerman K, Yen-Lieberman B, Daly TM. Impact of analytical variability on clinical interpretation of multiplex pneumococcal serology assays. *Clin Vaccine Immunol*. 2013;20:957–61.
11. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol*. 2012;130:S1–24.
12. Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. *Ann Allergy Asthma Immunol*. 2007;99:462–4.
13. Payne AB, Link-Gelles R, Azonobi I, Hooper WC, Beall BW, Jorgensen JH, et al. Active bacterial core surveillance team invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009. *Pediatr Infect Dis J*. 2013;32:1308–12.
14. Koffi KG, Sawadogo D, Meite M, Nanho DC, Tanoh ES, Attia AK, et al. Reduced levels of T-cell subsets CD4+ and CD8+ in homozygous sickle cell anaemia patients with splenic defects. *Hematol J*. 2003;4:363–5.
15. Balandya E, Reynolds T, Obaro S, Makani J. Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses. *Am J Hematol*. 2016;91:938–46.
16. Martin OO, Moquist KL, Hennessy JM, Nelson SC. Invasive pneumococcal disease in children with sickle cell disease in the pneumococcal conjugate vaccine era. *Pediatr Blood Cancer*. 2018;65(1).
17. Olibu G, Collins S, Sheppard C, Fry N, Dick M, Streetly A, et al. Risk of invasive pneumococcal disease in children with sickle cell disease in England: a national observational cohort study, 2010–2015. *Arch Dis Child*. 2018;103:643–7.
18. Vissers M, Wijmenga-Monsuur AJ, Knol MJ, Badoux P, van Houten MA, van der Ende A, et al. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. *PLOS ONE*. 2018;13, e0194823.
19. Varon E, Cohen R, Béchet S, Doit C, Levy C. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. *Vaccine*. 2015;33:6178–85.
20. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. *Clin Microbiol Rev*. 2012;25:409–19.
21. Ampofo K, Pavia AT, Chris S, Hersh AL, Bender JM, Blaschke AJ, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. *Pediatr Infect Dis J*. 2012;31:228–34.
22. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. *J Infect Dis*. 2007;196:1346–54.